Sugi Predict

Sugi Predict / Compounds / SCHEMBL3368196

SCHEMBL3368196

SCHEMBL3368196

CN(C(=O)OC(C)(C)C)c1ccc(I)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAX8 Q06710 1/20 0.49
▸ BRD4 O60885 2/20 0.42
▸ CREBBP Q92793 1/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NOTUM Q6P988 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ APP P05067 2/20 0.36
▸ MT-CO2 P00403 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ EPAS1 Q99814 1/20 0.35
▸ TGM2 P21980 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8018111 0.91 PAX8 (0.55) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL3364970 0.84 PAX8 (0.50) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL14384381 0.84 PAX8 (0.50) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL5360319 0.84 MT-CO2 (0.37) PAX8RAB9AAPPMT-CO2NPC1
SCHEMBL24448783 0.82 NPSR1 (0.58) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL2641765 0.82 PAX8 (0.49) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL4015896 0.82 PAX8 (0.49) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL15181430 0.82 MT-CO2 (0.51) PAX8BRD4CREBBPNPSR1RAB9A
SCHEMBL1817649 0.82 PAX8 (0.49) PAX8BRD4CREBBPNPSR1RAB9A
Water SCHEMBL27760152 0.82 PAX8 (0.49) PAX8BRD4CREBBPNPSR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-12-26 — — US disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 — — EP disclosed
US-11932624-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-03-19 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20230312479-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-10-05 — — US disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 — — WO disclosed
CN-115776887-A MDM2 degrading agents and uses thereof 凯麦拉医疗公司 2023-03-10 — — CN disclosed
US-6683201-B2 FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES HOFFMANN-LA ROCHE INC. 2004-01-27 — — US disclosed
US-6562851-B2 Antiinflammatory and antiasthmatic agents; inhibitors of alpha4 beta1 mediated cell adhesion AVENTIS PHARMA LIMITED (GB) 2003-05-13 — — US disclosed
EP-1303503-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 — — EP disclosed
US-20020156111-A1 Substituted bicyclic compounds AVENTIS PHARMA LIMITED (GB) 2002-10-24 — — US disclosed
US-20020038025-A1 Analine derivatives as OSC inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 — — US disclosed
EP-1177181-A1 SUBSTITUTED BICYCLIC COMPOUNDS Aventis Pharma Limited (GB) 2002-02-06 — — EP disclosed
WO-2002006189-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — WO disclosed
WO-2000068213-A1 SUBSTITUTED BICYCLIC COMPOUNDS AVENTIS PHARMA LIMITED (GB) 2000-11-16 — — WO disclosed
US-5432194-A Antiallergens, antinflammatory agents ABBOTT LABORATORIES (US) 1995-07-11 — — US disclosed
WO-1994026264-A1 (4-ALKOXYPYRAN-4-YL) SUBSTITUTED ARYLALKYLARYL-, ARYLALKENYLARYL-, AND ARYLALKYNYLARYLUREA INHIBITORS OF 5-LIPOXYGENASE ABBOTT LABORATORIES (US) 1994-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 PAX8 2057/4885BRD4 643/4885CREBBP 3349/4885
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, USP2, MYCBP2 PAX8 2515/4885BRD4 271/4885CREBBP 2210/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 PAX8 2686/4885BRD4 254/4885CREBBP 2776/4885
US-20230312479-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP PAX8 3893/4885BRD4 2694/4885CREBBP 1774/4885
US-20020038025-A1 Analine derivatives as OSC inhibitors LSS, CYP51A1, CYP46A1 PAX8 4840/4885BRD4 4712/4885CREBBP 4739/4885
US-11932624-B2 MDM2 degraders and uses thereof MDM2, TP53, MDM4 PAX8 2057/4885BRD4 643/4885CREBBP 3349/4885
US-20020156111-A1 Substituted bicyclic compounds VCAM1, ITGA1, ITGA5 PAX8 2513/4885BRD4 2807/4885CREBBP 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.